Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
- 31 July 2012
- journal article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 104 (16), 1263-1264
- https://doi.org/10.1093/jnci/djs312
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons LearnedJNCI Journal of the National Cancer Institute, 2012
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer PatientsJNCI Journal of the National Cancer Institute, 2012
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 TrialJNCI Journal of the National Cancer Institute, 2012
- CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in DenmarkJNCI Journal of the National Cancer Institute, 2011
- CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifenBreast Cancer Research, 2010